Book an appointment

Urologic oncology · 2026

Prostate cancer treatment,
robotic surgery + PSMA imaging.

Robotic radical prostatectomy from $11,500. PSMA PET-CT staging, NMPA-approved ARSI (apalutamide, enzalutamide, darolutamide, abiraterone), proton therapy, and active-surveillance pathway at top urology centres.

Get a written quote Top urology centres

$11,500–18k

Robotic prostatectomy

vs $35,000–80,000 in the US

Partner clinic quotes 2024

PSMA PET-CT

Available

68Ga-PSMA-11 and 18F-DCFPyL at top centres

Centre programs

NMPA

ARSI approved

Apalutamide, enzalutamide, darolutamide, abiraterone, talazoparib

NMPA approvals

MDT

Standard pathway

Urology + medical onc + radiation onc + pathology

Standard at Class A

Bilingual

Pathology + Gleason

ISUP grade, ETE, margin and node status

Service standard

Active surveillance

Pathway available

For low-risk and selected favourable intermediate-risk

NCCN-aligned

Tiers & pricing

Six tiers, transparent pricing.

Workup

Diagnostic + staging

MRI prostate, MRI-targeted + systematic biopsy, PSMA PET-CT for unfavourable intermediate / high risk.

$2,500–4,500

Low-risk

Active surveillance

PSA + MRI + repeat biopsy schedule for low-risk and selected favourable intermediate.

$650–1,400 / annual

Standard surgery

Robotic radical prostatectomy

da Vinci RARP with bilateral pelvic LN dissection. Nerve-sparing where indicated.

$11,500–18,000

Adjuvant / definitive

Radiation (EBRT / SBRT)

Hypofractionation standard. SBRT in 5 fractions for selected. IMRT / VMAT widely available.

$8,500–14,500

Specialist RT

Proton therapy

Available at Cancer Hospital of CAMS and Shanghai PHIC. Patient selection is case-specific.

$45,000–80,000

Systemic

ARSI / chemotherapy / PARP

Apalutamide, enzalutamide, darolutamide, abiraterone, docetaxel, cabazitaxel, olaparib, talazoparib.

$280–1,800 / month

Top hospitals

Six centres
open to international patients.

Beijing

PUMC Urology 北京协和医院

Academic urologic oncology · diagnostic excellence · large robotic volume

Shanghai

Fudan Shanghai Cancer Center 复旦大学附属肿瘤医院

Class A · MDT urologic oncology · trial site · large adjuvant volume

Beijing

Cancer Hospital of CAMS 中国医学科学院肿瘤医院

National cancer reference · proton therapy · MDT prostate cancer

Shanghai

Renji Hospital, SJTU 仁济医院

Class A · large urology service · robotic prostatectomy programme

Guangzhou

Sun Yat-sen University Cancer Center 中山大学肿瘤防治中心

Class A · regional reference · trial site

Shanghai

Shanghai Proton Heavy Ion Center 上海质子重离子医院

Proton + heavy-ion therapy · prostate cancer indication

Cost comparison

China vs US vs UK,
real pricing.

China
United States
United Kingdom
Robotic prostatectomy
$11,500–$18,000
$35,000–$80,000
£15,000–£28,000
Open radical prostatectomy
$8,500–$13,500
$25,000–$50,000
£10,000–£18,000
PSMA PET-CT
$1,800–$3,500
$5,000–$8,000
£2,200–£4,000
EBRT / IMRT course
$8,500–$14,500
$30,000–$70,000
£12,000–£22,000
Apalutamide (monthly)
$1,200–$1,800
$11,000–$13,500
£3,500–£5,500

Sources: NCCN-aligned pricing, CMS HCUP 2023, NHS specialist commissioning 2024, NMPA-listed pricing, partner-hospital itemized quotes 2024–2025. Indicative; case-specific.

FAQ

Frequently asked questions.

Why China for prostate cancer?
China has very high robotic prostatectomy volumes at flagship Class A centres (PUMC, Renji, Fudan Cancer, Cancer Hospital of CAMS), with surgeons routinely exceeding 200–300 RARPs per year. NMPA-approved ARSI and chemotherapy access mirrors Western pipelines (apalutamide, enzalutamide, darolutamide, abiraterone, talazoparib, olaparib for HRR-mutated CRPC) at 30–60% off US prices. PSMA PET-CT staging is widely available.
What does the standard pathway look like?
Diagnostic — multi-parametric MRI prostate (mpMRI) with PI-RADS scoring; targeted + systematic biopsy under fusion ultrasound; ISUP / Gleason grading; for unfavourable intermediate / high risk, PSMA PET-CT for distant staging. Treatment — risk-stratified by NCCN: very low / low / favourable intermediate often suitable for active surveillance; unfavourable intermediate / high risk treated with RARP + adjuvant ADT/RT or definitive RT + ADT; metastatic disease treated with ADT + ARSI (or + docetaxel) per CHAARTED / LATITUDE / TITAN / ENZAMET / ARASENS protocols.
Is robotic prostatectomy safer than open?
RARP and open radical prostatectomy have similar oncological outcomes in published meta-analyses; RARP has lower blood loss, shorter inpatient stay, and modestly improved continence and erectile function recovery in expert hands. Surgeon experience matters more than approach. Top Chinese centres routinely perform RARP with case volumes exceeding most Western private practices. Open prostatectomy is also offered at lower cost for patients without anatomic indication for robotic.
What about PSMA PET-CT?
PSMA PET-CT (68Ga-PSMA-11 or 18F-DCFPyL) is increasingly the standard for biochemical recurrence and unfavourable intermediate / high risk staging, replacing CT + bone scan in many centres. Indicative cost $1,800–$3,500 in China vs $5,000–$8,000 in the US. Available at major nuclear medicine departments — confirm tracer availability when booking. PSMA-targeted radioligand therapy (177Lu-PSMA) is available in select trial settings; commercial NMPA approval pending as of late 2025.
What about active surveillance?
Active surveillance is the recommended approach for very-low and low-risk prostate cancer per NCCN, EAU and AUA guidelines, and is increasingly offered for selected favourable intermediate-risk patients. Standard schedule: PSA every 6 months; mpMRI annually for first 2 years then risk-stratified; confirmatory biopsy at 12 months and risk-based thereafter. We coordinate annual surveillance trips for AS patients with bilingual report and home-team handover.
Will my home urologist accept the report?
Yes — bilingual MDT reports follow Western conventions: NCCN risk stratification; AJCC TNM staging; explicit Gleason / ISUP grading; PSA history with PSAdt where applicable; comprehensive imaging interpretation; explicit treatment recommendation with rationale; planned follow-up schedule. We have not had a Western urology team decline to accept such a report. Peer-to-peer with operating surgeon offered free.

Related guides

Cancer Treatment Hub

All oncology pathways in China.

Read the guide

Proton Therapy

When proton therapy adds value over photon IMRT.

Read the guide

Second Opinion

Independent urologic oncology second opinion from $250.

Read the guide

Clinical Trials

Prostate cancer trial screening including PSMA-RLT.

Read the guide

Hereditary Screening

BRCA / HOXB13 / Lynch screening for high-risk men.

Read the guide

Records Translation

Bilingual translation of pathology and imaging.

Read the guide

Send your PSA + biopsy
for an MDT review.

Upload your PSA history, biopsy report, MRI and any prior imaging. We coordinate a written MDT review at a partner urology centre with treatment plan, indicative cost and active-surveillance vs treatment recommendation.

Request a quote Cancer treatment overview

This page is for general information only and does not constitute medical advice. Prostate cancer treatment depends on risk group, biomarkers, life expectancy and individual factors. We do not guarantee outcomes.